Achiko AG Announces Annual Results for the Year Ended December 31, 2021 ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended December...

AptameX Production and Commercialization Update Company has commenced shipping and will book first sales in May 2022Reorganized production line able to meet stronger than expected demand for Achiko AG’s innovative DNA aptamer saliva-based rapid...

Achiko Working Towards a Solution for Frequent Global Mass COVID-19 Testing ZURICH, Switzerland, July 13, 2021 (GLOBE NEWSWIRE) -- Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company currently developing technologies that seek to...

Achiko’s Joint Venture Partner Obtains a Distribution Certificate for AptameX, a Novel Diagnostic Test for Covid-19 in Indonesia, and Commences Product Registration Achiko AG’s Joint Venture Partner PT Indonesia Farma Medis (IFM) Obtains Medical Device Distribution CertificateAchiko Subsequently Commenced Product Registration with its Partners with a View to...